Viemed Healthcare, Inc.
VMD
$7.80
$0.405.41%
| Weiss Ratings | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Good | |||
| Risk Index | Weak | |||
| Risk Grade | D+ | |||
| Reward Grade | B | |||
| Rating Factors | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Excellent | |||
| Efficiency Index | Good | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.94 | |||
| Price History | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.51% | |||
| 30-Day Total Return | -7.47% | |||
| 60-Day Total Return | -11.36% | |||
| 90-Day Total Return | -14.19% | |||
| Year to Date Total Return | -4.06% | |||
| 1-Year Total Return | -16.49% | |||
| 2-Year Total Return | -15.40% | |||
| 3-Year Total Return | 76.07% | |||
| 5-Year Total Return | 152.43% | |||
| 52-Week High % Change | -26.00% | |||
| 52-Week Low % Change | 19.09% | |||
| Price | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.00 | |||
| 52-Week Low Price | $6.21 | |||
| 52-Week Low Price (Date) | Jun 26, 2024 | |||
| 52-Week High Price (Date) | Mar 11, 2024 | |||
| Valuation | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 288.13M | |||
| Enterprise Value | 279.36M | |||
| Price/Earnings (TTM) | 28.74 | |||
| Earnings Per Share (TTM) | 0.26 | |||
| Earnings Per Share Growth | 10.09% | |||
| Price/Earnings To Growth | 2.85 | |||
| Price/Sales (TTM) | 1.41 | |||
| Price/Book (Q) | 2.31 | |||
| Enterprise Value/Revenue (TTM) | 1.30 | |||
| Price | $7.80 | |||
| Enterprise Value/EBITDA (TTM) | 6.60 | |||
| Enterprise Value/EBIT | 16.05 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 40.78M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 337 504 3802 | |||
| Address | 625 East Kaliste Saloom Road Lafayette, LA 70508 | |||
| Website | www.viemed.com | |||
| Country | United States | |||
| Year Founded | 2006 | |||
| Profitability | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 8.12% | |||
| Profit Margin | 4.86% | |||
| Management Effectiveness | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 6.82% | |||
| Return on Equity | 8.88% | |||
| Income Statement | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 214.30M | |||
| Total Revenue (TTM) | 214.30M | |||
| Revenue Per Share | $5.26 | |||
| Gross Profit (TTM) | 129.18M | |||
| EBITDA (TTM) | 42.32M | |||
| EBIT (TTM) | 17.40M | |||
| Net Income (TTM) | 10.43M | |||
| Net Income Avl. to Common (TTM) | 10.43M | |||
| Total Revenue Growth (Q YOY) | 17.41% | |||
| Earnings Growth (Q YOY) | 33.78% | |||
| EPS Diluted (TTM) | 0.26 | |||
| EPS Diluted Growth (Q YOY) | 42.57% | |||
| Balance Sheet | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 11.35M | |||
| Cash Per Share (Q) | $0.28 | |||
| Total Current Assets (Q) | 47.70M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 126.80M | |||
| Current Ratio (Q) | 1.309 | |||
| Book Value Per Share (Q) | $3.21 | |||
| Total Assets (Q) | 169.53M | |||
| Total Current Liabilities (Q) | 36.44M | |||
| Total Debt (Q) | 7.26M | |||
| Total Liabilities (Q) | 42.73M | |||
| Total Common Equity (Q) | 124.96M | |||
| Cash Flow | VMD - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -28.99M | |||
| Cash from Financing (TTM) | -7.12M | |||
| Net Change in Cash (TTM) | 1.27M | |||
| Levered Free Cash Flow (TTM) | 4.77M | |||
| Cash from Operations (TTM) | 37.39M | |||
